News Sentiment

ANGO sentiment intelligence

AngioDynamics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 54 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Instruments & Supplies Read-through group
Latest close 12.79 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Earnings

77/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

-2.3% over one week, +5.7% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

AngioDynamics rises as Freedom Broker raises stock price target to $17

Market Reaction

Balanced read

63/100 confidence

News tone and price action are not far from neutral.

Primary event Earnings 77/100 classification
One-week reaction -2.3% Price reacting lower
Trend fit Trend active 5.7% over four weeks
Fair value 44.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 23
Neutral 22
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
TradingView 8
Stock Titan 6
Moomoo 4
Investing.com 4
TradingKey 3
Seeking Alpha 2
Simply Wall Street 2
Market source 2

Event Lens

What the news is about

Classified themes
Earnings 26
Market update 12
Regulatory and legal 9
Analyst action 6
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 54
Freedom Broker Direct company coverage

AngioDynamics rises as Freedom Broker raises stock price target to $17

Freedom Broker analysts have raised their price target for AngioDynamics (ANGO) to $17, maintaining a "Buy" rating, following strong financial results. The NanoKnife platform is highlighted as a key growth driver, with expanded insurance coverage and increased disposable use. The

Tone
Positive 82/100
Event
Analyst action
Published
16 Jul 2026 18:42
Source
Freedom Broker
Investing.com Direct company coverage

H.C. Wainwright raises AngioDynamics stock price target on growth

H.C. Wainwright has increased its price target for AngioDynamics (NASDAQ:ANGO) shares to $19 from $16, maintaining a Buy rating, following the company's strong fiscal fourth-quarter and full-year 2026 results. The medical technology firm reported significant growth in net sales,

Tone
Positive 75/100
Event
Analyst action
Published
16 Jul 2026 11:41
Source
Investing.com
Simply Wall Street Direct company coverage

AngioDynamics (ANGO) Stock Faces Profitability Question As Q4 EPS Loss Deepens Bearish Narrative

AngioDynamics (ANGO) concluded FY 2026 with a Q4 basic EPS loss of US$0.27 and a full-year basic EPS loss of US$0.88 on US$320.2 million in revenue, continuing a trend of net losses. While forecasts project 72.2% annual earnings growth and profitability within three years, the co

Tone
Negative 28/100
Event
Earnings
Published
16 Jul 2026 01:13
Source
Simply Wall Street
Investing.com Direct company coverage

Freedom Broker raises AngioDynamics stock price target to $17 on margin outlook

Freedom Broker increased its price target for AngioDynamics (NASDAQ: ANGO) to $17.00 from $16.00, reiterating a Buy rating due to an improved margin outlook. This revision follows an upward adjustment of fiscal 2027 adjusted EBITDA estimates by 29% and expectations of growing mar

Tone
Positive 74/100
Event
Analyst action
Published
15 Jul 2026 15:43
Source
Investing.com
TradingView Direct company coverage

AngioDynamics Q4 Earnings Beat Estimates, Gross Margin Expands

AngioDynamics (ANGO) reported an adjusted loss per share of 7 cents for Q4 fiscal 2026, which was narrower than analysts' expectations, and full-year fiscal 2026 adjusted loss also beat estimates. The company's Q4 revenues rose 8% year-over-year to $86.6 million, exceeding the Za

Tone
Positive 71/100
Event
Earnings
Published
15 Jul 2026 14:43
Source
TradingView
TradingView Direct company coverage

ANGIODYNAMICS INC FY 2026: Revenue $320.17M, EPS ($0.88) — 10-K Summary

AngioDynamics Inc. reported fiscal year 2026 revenue of $320.17M, a 9.5% increase from the previous year, with a net loss of ($36.74M) and diluted loss per share of ($0.88). The revenue growth was primarily driven by Med Tech, and the company is restructuring its manufacturing fo

Tone
Negative 38/100
Event
Earnings
Published
14 Jul 2026 19:40
Source
TradingView
AlphaStreet Direct company coverage

AngioDynamics Releases Q4 2026 Financial Results

AngioDynamics, Inc. (ANGO) reported Q4 2026 adjusted diluted loss per share of -$0.07, outperforming the -$0.09 expected loss. The company's revenue reached $86.6 million, surpassing the consensus estimate by 7.9% and marking an 8% year-over-year increase. AngioDynamics also prov

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 12:23
Source
AlphaStreet
Stock Titan Direct company coverage

Record 2026 sales as AngioDynamics (NASDAQ: ANGO) grows Med Tech 18%

AngioDynamics (NASDAQ: ANGO) reported record fiscal 2026 results with pro forma net sales of $320.2 million, a 9.4% increase, driven by an 18.4% rise in Med Tech revenue. Despite a GAAP net loss of $36.7 million, adjusted EBITDA increased to $13.2 million. The company issued fisc

Tone
Positive 69/100
Event
Earnings
Published
14 Jul 2026 11:14
Source
Stock Titan
Stock Titan Direct company coverage

NanoKnife Medicare Coverage Takes Effect for Qualifying Patients

AngioDynamics (NASDAQ: ANGO) announced its fourth quarter and full fiscal year 2026 financial results, highlighting a year of consistent execution and significant growth in its Med Tech segment. The company reported full-year Med Tech growth over 18%, driven by platform technolog

Tone
Positive 74/100
Event
Earnings
Published
14 Jul 2026 10:14
Source
Stock Titan
10TV Direct company coverage

AngioDynamics: Fiscal Q4 Earnings Snapshot

AngioDynamics Inc. (ANGO) reported a fiscal fourth-quarter loss of $11.4 million, or 27 cents per share, with adjusted losses at 7 cents per share. The medical device maker posted revenue of $86.6 million for the quarter. For the full year, the company's loss widened to $36.7 mil

Tone
Negative 34/100
Event
Earnings
Published
14 Jul 2026 06:18
Source
10TV
TradingView Direct company coverage

AngioDynamics Inc expected to post a loss of 9 cents a share - Earnings Preview

AngioDynamics Inc is projected to report a loss of 9 cents per share, according to this earnings preview. The article, sourced from Reuters, specifically highlights the anticipated financial performance for the company. Readers are prompted to start a free trial to access the ful

Tone
Negative 29/100
Event
Earnings
Published
10 Jul 2026 12:40
Source
TradingView
AboutLawsuits.com Direct company coverage

Vortex Port Lawsuit Claims Defective AngioDynamics Device Caused Infection, Pulmonary Embolism

A South Carolina woman has filed a lawsuit against AngioDynamics and Navilyst Medical Inc., alleging that their defective Vortex port catheter caused her to suffer pulmonary embolisms and a serious infection, necessitating its surgical removal. The complaint claims the defendants

Tone
Neutral 50/100
Event
Regulatory and legal
Published
07 Jul 2026 15:11
Source
AboutLawsuits.com
Simply Wall Street Direct company coverage

AngioDynamics (Nasdaq:ANGO) - Stock Analysis

This report provides a comprehensive stock analysis of AngioDynamics (Nasdaq:ANGO), detailing its financial performance, future growth prospects, and recent developments. The company, a medical technology firm specializing in devices for peripheral vascular disease and oncology,

Tone
Positive 67/100
Event
Market update
Published
07 Jul 2026 11:40
Source
Simply Wall Street
TradingView Direct company coverage

Price to earnings forward of AngioDynamics, Inc. – NASDAQ:ANGO

This article provides the "Price to earnings forward" value for AngioDynamics, Inc. (NASDAQ: ANGO) within the TradingView platform. It also lists the financial data providers and various sections of the TradingView website.

Tone
Neutral 50/100
Event
Earnings
Published
06 Jul 2026 00:40
Source
TradingView
TradingView Direct company coverage

Price to sales forward of AngioDynamics, Inc. – NASDAQ:ANGO

This article provides financial information for AngioDynamics, Inc. (NASDAQ: ANGO), specifically its forward price-to-sales ratio. It lists the company's stock market data and indicates that the market is currently closed with no trades. The core content appears to be a data poin

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 01:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of AngioDynamics, Inc. – LS:A0B9A5

This article provides financial data for AngioDynamics, Inc. (A0B9A5) on TradingView, specifically focusing on its forward price-to-sales ratio. It lists market information, financial overviews, and other technical and fundamental data points available for the company.

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 00:09
Source
TradingView